Literature DB >> 11166908

Humoral and cell-mediated immune responses of foxes (Vulpes vulpes) after experimental primary and secondary oral vaccination using SAG2 and V-RG vaccines.

M Lambot1, E Blasco, J Barrat, F Cliquet, B Brochier, C Renders, N Krafft, J Bailly, M Munier, M F Aubert, P P Pastoret.   

Abstract

Humoral and cell-mediated immune responses of 36 captive foxes to two oral vaccines against rabies currently used for foxes in Europe were studied. The Street Alabama Dufferin (SAD) mutant Gif (SAG2) vaccine has been selected by double mutation from the SAD virus. The vaccinia recombinant virus (V-RG) expresses the rabies glycoprotein. Both vaccines induce similar humoral and cell-mediated responses after primary and secondary oral administration. We observed a typical anamnestic response, although of a limited duration, after the booster vaccination. Therefore, our results suggested that two successive oral vaccination campaigns should not significantly improve the immunisation of foxes. Lymphocyte in vitro proliferative response to the SAD antigen highlighted the presence in blood of a T-cell specific memory 6 months after vaccination. The synthesis of several vulpine cytokines was detected in peripheral blood mononuclear cells (PBMC) stimulated by SAD antigen via reverse transcription polymerase chain amplification. The data showed a concomitant expression of interleukin (IL)-4 and interferon-gamma in PBMC of vaccinated foxes. No change was detected in the level of IL-2, IL-10 and IL-12 synthesis, whereas the pro-inflammatory cytokine tumour necrosis factor-alpha seemed involved in the activation of naive T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11166908     DOI: 10.1016/s0264-410x(00)00321-2

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

Review 1.  Oral vaccination of wildlife using a vaccinia-rabies-glycoprotein recombinant virus vaccine (RABORAL V-RG®): a global review.

Authors:  Joanne Maki; Anne-Laure Guiot; Michel Aubert; Bernard Brochier; Florence Cliquet; Cathleen A Hanlon; Roni King; Ernest H Oertli; Charles E Rupprecht; Caroline Schumacher; Dennis Slate; Boris Yakobson; Anne Wohlers; Emily W Lankau
Journal:  Vet Res       Date:  2017-09-22       Impact factor: 3.683

2.  Comparable Long-Term Rabies Immunity in Foxes after IntraMuscular and Oral Application Using a Third-Generation Oral Rabies Virus Vaccine.

Authors:  Verena Te Kamp; Virginia Friedrichs; Conrad M Freuling; Ad Vos; Madlin Potratz; Antonia Klein; Luca M Zaeck; Elisa Eggerbauer; Peter Schuster; Christian Kaiser; Steffen Ortmann; Antje Kretzschmar; Katharina Bobe; Michael R Knittler; Anca Dorhoi; Stefan Finke; Thomas Müller
Journal:  Vaccines (Basel)       Date:  2021-01-14

3.  Antibody response to Raboral VR-G® oral rabies vaccine in captive and free-ranging black-backed jackals (Canis mesomelas).

Authors:  Katja N Koeppel; Peter Geertsma; Brian F Kuhn; Ockert L Van Schalkwyk; Peter N Thompson
Journal:  Onderstepoort J Vet Res       Date:  2022-02-10       Impact factor: 1.792

Review 4.  Twenty year experience of the oral rabies vaccine SAG2 in wildlife: a global review.

Authors:  Philippe Mähl; Florence Cliquet; Anne-Laure Guiot; Enel Niin; Emma Fournials; Nathalie Saint-Jean; Michel Aubert; Charles E Rupprecht; Sylvie Gueguen
Journal:  Vet Res       Date:  2014-08-10       Impact factor: 3.683

5.  First trials of oral vaccination with rabies SAG2 dog baits in Morocco.

Authors:  Sami Darkaoui; Franck Boué; Jean Michel Demerson; Ouafaa Fassi Fihri; Khadija Id Sidi Yahia; Florence Cliquet
Journal:  Clin Exp Vaccine Res       Date:  2014-06-20

6.  Safety, efficacy and immunogenicity evaluation of the SAG2 oral rabies vaccine in Formosan ferret badgers.

Authors:  Ai-Ping Hsu; Chun-Hsien Tseng; Jacques Barrat; Shu-Hwae Lee; Yu-Hua Shih; Marine Wasniewski; Philippe Mähl; Chia-Chia Chang; Chun-Ta Lin; Re-Shang Chen; Wen-Jane Tu; Florence Cliquet; Hsiang-Jung Tsai
Journal:  PLoS One       Date:  2017-10-04       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.